Literature DB >> 25656438

Muscle and Bone Impairment in Children With Marfan Syndrome: Correlation With Age and FBN1 Genotype.

Elsa Haine1, Jean-Pierre Salles1,2, Philippe Khau Van Kien3, Françoise Conte-Auriol2,4, Isabelle Gennero2,5, Aurélie Plancke3, Sophie Julia6, Yves Dulac7, Maithé Tauber1,2, Thomas Edouard1,2.   

Abstract

Marfan syndrome (MFS) is a rare connective tissue disorder caused by mutation in the gene encoding the extracellular matrix protein fibrillin-1 (FBN1), leading to transforming growth factor-beta (TGF-β) signaling dysregulation. Although decreased axial and peripheral bone mineral density (BMD) has been reported in adults with MFS, data about the evolution of bone mass during childhood and adolescence are limited. The aim of the present study was to evaluate bone and muscle characteristics in children, adolescents, and young adults with MFS. The study population included 48 children and young adults (22 girls) with MFS with a median age of 11.9 years (range 5.3 to 25.2 years). The axial skeleton was analyzed at the lumbar spine using dual-energy X-ray absorptiometry (DXA), whereas the appendicular skeleton (hand) was evaluated using the BoneXpert system (with the calculation of the Bone Health Index). Muscle mass was measured by DXA. Compared with healthy age-matched controls, bone mass at the axial and appendicular levels and muscle mass were decreased in children with MFS and worsened from childhood to adulthood. Vitamin D deficiency (<50 nmol/L) was found in about a quarter of patients. Serum vitamin D levels were negatively correlated with age and positively correlated with lumbar spine areal and volumetric BMD. Lean body mass (LBM) Z-scores were positively associated with total body bone mineral content (TB-BMC) Z-scores, and LBM was an independent predictor of TB-BMC values, suggesting that muscle hypoplasia could explain at least in part the bone loss in MFS. Patients with a FBN1 premature termination codon mutation had a more severe musculoskeletal phenotype than patients with an inframe mutation, suggesting the involvement of TGF-β signaling dysregulation in the pathophysiologic mechanisms. In light of these results, we recommend that measurement of bone mineral status should be part of the longitudinal clinical investigation of MFS children.
© 2015 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE MINERAL DENSITY; DXA; FIBRILLIN-1; MARFAN SYNDROME; PUBERTY; TGF-β

Mesh:

Substances:

Year:  2015        PMID: 25656438     DOI: 10.1002/jbmr.2471

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  14 in total

Review 1.  Fibrillin microfibrils in bone physiology.

Authors:  Silvia Smaldone; Francesco Ramirez
Journal:  Matrix Biol       Date:  2015-09-25       Impact factor: 11.583

Review 2.  When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Authors:  Smita Jha; Marquis Chapman; Kelly Roszko
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

3.  "Reverse Genomics" Predicts Function of Human Conserved Noncoding Elements.

Authors:  Amir Marcovitz; Robin Jia; Gill Bejerano
Journal:  Mol Biol Evol       Date:  2016-01-06       Impact factor: 16.240

4.  A Piece of the Puzzle: The Bone Health Index of the BoneXpert Software Reflects Cortical Bone Mineral Density in Pediatric and Adolescent Patients.

Authors:  Michael M Schündeln; Laura Marschke; Jens J Bauer; Pia K Hauffa; Bernd Schweiger; Dagmar Führer-Sakel; Harald Lahner; Thorsten D Poeppel; Cordula Kiewert; Berthold P Hauffa; Corinna Grasemann
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

5.  Truncated C-terminus of fibrillin-1 induces Marfanoid-progeroid-lipodystrophy (MPL) syndrome in rabbit.

Authors:  Mao Chen; Bing Yao; Qiangbing Yang; Jichao Deng; Yuning Song; Tingting Sui; Lina Zhou; HaoBing Yao; Yuanyuan Xu; Hongsheng Ouyang; Daxin Pang; Zhanjun Li; Liangxue Lai
Journal:  Dis Model Mech       Date:  2018-04-09       Impact factor: 5.758

6.  Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.

Authors:  Celine Saint-Laurent; Stephanie Garcia; Vincent Sarrazy; Karine Dumas; Florence Authier; Sophie Sore; Albert Tran; Philippe Gual; Isabelle Gennero; Jean-Pierre Salles; Elvire Gouze
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

Review 7.  When flexibility is not necessarily a virtue: a review of hypermobility syndromes and chronic or recurrent musculoskeletal pain in children.

Authors:  Marco Cattalini; Raju Khubchandani; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2015-10-06       Impact factor: 3.054

8.  Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts.

Authors:  Kazuhiro Umeyama; Kota Watanabe; Masahito Watanabe; Keisuke Horiuchi; Kazuaki Nakano; Masateru Kitashiro; Hitomi Matsunari; Tokuhiro Kimura; Yoshimi Arima; Oltea Sampetrean; Masaki Nagaya; Masahiro Saito; Hideyuki Saya; Kenjiro Kosaki; Hiroshi Nagashima; Morio Matsumoto
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379

9.  Genotype-Phenotype Correlation in Children: The Impact of FBN1 Variants on Pediatric Marfan Care.

Authors:  Veronika C Stark; Flemming Hensen; Kerstin Kutsche; Fanny Kortüm; Jakob Olfe; Peter Wiegand; Yskert von Kodolitsch; Rainer Kozlik-Feldmann; Götz C Müller; Thomas S Mir
Journal:  Genes (Basel)       Date:  2020-07-15       Impact factor: 4.096

Review 10.  The Molecular Genetics of Marfan Syndrome.

Authors:  Qiu Du; Dingding Zhang; Yue Zhuang; Qiongrong Xia; Taishen Wen; Haiping Jia
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.